Association between transient receptor potential melastatin genotypes and the prostate surface antigen levels in BPH patients

Royronald Ochieng Ongonga; Nelson Menza; Rodgers Norman Demba

doi:10.18203/2320-6012.ijrms20241222

Authors

Royronald Ochieng Ongonga Department of Medical Laboratory Science, Kenyatta University, Nairobi, Kenya
Nelson Menza Department of Medical Laboratory Science, Kenyatta University, Nairobi, Kenya
Rodgers Norman Demba Department of Medical Laboratory Science, Maseno University, Maseno, Kenya

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241222

Keywords:

BPH SNP’s, Genotype, PSA, TRPM

Abstract

Background: Benign Prostate Hyperplasia (BPH) is a prevalent condition among older males, characterized by an enlarged prostate gland leading to lower urinary tract symptoms and impacting quality of life. Transient receptor potential melastatin (TRPM) genes regulate various physiological processes.

Methods: We studied 194 BPH patients and 194 healthy controls, genotyping six selected TRPM gene SNPs. PSA levels were measured using the Cobas® e411 analyzer.

Results: Prostate-specific antigen (PSA) levels were significantly higher in BPH patients (135.76±578.03 ng/mL) than in controls (2.01±1.09 ng/mL). TRPM2 (rs168355) and TRPM7 (rs2362295) genotypes were significantly associated with elevated PSA levels. The TRPM2 GG genotype was associated with decrease in the likelihood of severe PSA levels (OR=0.34, 95% CI: 0.12-0.96, P=0.034), while the TRPM7 CC genotype showed increased odds for severe PSA levels (OR=1.48, 95% CI: 1.08-3.56, P=0.041).

Conclusions: Our findings suggest a potential link between TRPM gene variants and the severity of prostatic changes reflected in PSA secretions, indicating the need for further research to understand the underlying mechanisms and clinical implications.

Metrics

Metrics Loading ...

References

Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am. 2016;43(3):279-88.

Tong Y, Zhou R yuan. Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia. Dobrzyn A, editor. Mediators Inflamm. 2020;2020:1-7.

Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019;8(5):529-39.

Schedlich LJ, Bennetts BH, Morris BJ. Primary Structure of a Human Glandular Kallikrein Gene. DNA. 2017;6(5):429-37.

Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21(2):383-91.

Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in cancer prostate. Indian J Surg Oncol. 2012;3(2):120-9.

Huang Y, Fliegert R, Guse AH, Lü W, Du J. A structural overview of the ion channels of the TRPM family. Cell Calcium. 2020;85:102111.

Samanta A, Hughes TET, Moiseenkova-Bell VY. Transient Receptor Potential (TRP) Channels. In: Harris JR, Boekema EJ, editors. Membrane Protein Complexes: Structure and Function. Singapore: Springer Singapore; 2018:141-65.

Phelps CB, Gaudet R. The role of the n terminus and transmembrane domain of TRPM8 in channel localization and tetramerization. J Biol Chem. 2007;282(50):36474-80.

Zholos A. Pharmacology of transient receptor potential melastatin channels in the vasculature. Brit J Pharmacol. 201;159(8):1559-71.

Earley S, Brayden JE. Transient receptor potential channels in the vasculature. Physiological reviews. 2015;95(2):645-90.

Ghosh D, Syed AU, Prada MP, Nystoriak MA, Santana LF, Nieves-Cintrón M, et al. Calcium channels in vascular smooth muscle. Adv Pharmacol San Diego Calif. 2017;78:49-87.

Marini M, Titiz M, Souza Monteiro De Araújo D, Geppetti P, Nassini R, De Logu F. TRP Channels in Cancer: Signaling Mechanisms and Translational Approaches. Biomolec. 2023;13(10):1557.

Duitama M, Vargas-López V, Casas Z, Albarracin SL, Sutachan JJ, Torres YP. TRP Channels role in pain associated with neurodegenerative diseases. Front Neurosci. 2020;14:782.

Udoh Ea, Essiet Iu, Ekwere Pd. Correlation between prostate size and age of patients evaluated for symptomatic benign prostatic hyperplasia. Ibom Med J. 2020;13(1):12-7.

Ang M, Rajcic B, Foreman D, Moretti K, O’Callaghan ME. Men presenting with prostate‐specific antigen ( PSA ) values of over 100 ng/mL. BJU Int. 2016;117(S4):68-75.

Abotsi E, Adanu KK, Bansah EC. Serum prostate-specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia. Afr J Prim Health Care Fam Med. 2022;14(1).

Hussein AA, Baban R, Hussein A. Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. Baghdad J Biochem Appl Biol Sci. 2020;1(01):18-26.

Sciarra A, Mariotti G, Salciccia S, Gomez AA, Monti S, Toscano V, et al. Prostate growth and inflammation. J Steroid Biochem Mol Biol. 2008;108(3-5):254-60.

Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012;19(Suppl 1):10-7.

Filella X, Foj L. Prostate cancer detection and prognosis: from prostate specific antigen (psa) to exosomal biomarkers. Int J Mol Sci. 2016;17(11):1784.

Maliougina M, El Hiani Y. TRPM2: bridging calcium and ROS signaling pathways-implications for human diseases. Front Physiol. 2023;14:1217828.

Miller BA, Zhang W. TRP channels as mediators of oxidative stress. Adv Exp Med Biol. 2011;704:531-44.

Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, Yoshida T, et al. LTRPC2 Ca2+-permeable channel activated by changes in redox status confers susceptibility to cell death. Mol Cell. 2002;9(1):163-73.

Kaneko S, Kawakami S, Hara Y, Wakamori M, Itoh E, Minami T, et al. A Critical Role of TRPM2 in neuronal cell death by hydrogen peroxide. J Pharmacol Sci. 2006;101(1):66-76.

Knowles H, Li Y, Perraud AL. The TRPM2 ion channel is an oxidative stress and metabolic sensor regulating innate immunity and inflammation. Immunol Res. 2013;55(1–3):241-8.

Ali ES, Chakrabarty B, Ramproshad S, Mondal B, Kundu N, Sarkar C, et al. TRPM2-mediated Ca2+ signaling as a potential therapeutic target in cancer treatment: an updated review of its role in survival and proliferation of cancer cells. Cell Commun Signal CCS. 2023;21(1):145.

Mogensen I, Alving K, Jacinto T, Fonseca J, Janson C, Malinovschi A. Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007-12. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2018;48(8):935-43.

Schmitz C, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, et al. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell. 2003;114(2):191-200.

Sun Y, Sukumaran P, Schaar A, Singh BB. TRPM7 and its role in neurodegenerative diseases. Channels. 2015;9(5):253-61.

Nadler MJS, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, et al. LTRPC7 is a Mg·ATP-regulated divalent cation channel required for cell viability. Nature. 2001;411(6837):590-5.